The Board believes that Brent's leadership will be the lynchpin to take the Ultroid® system to the next level through expanded sales and distribution, capturing the system's full potential in a multi-billion dollar segment.
St. Petersburg, FL (PRWEB) July 8, 2008
Vascular Technologies Inc. and Ultroid Technologies, Inc., announce today that Brent Willis, former CCO of InBev and CEO of Cott Corporation, is appointed as Chief Executive Officer and member of the Boards of directors, effective immediately. Vascular Technologies, Inc. is the owner of the new Ultroid® medical device that has shown over 90% effectiveness in the treatment of hemorrhoids, which affect more than 75% of the world's over-50 population. Unlike current surgical treatments, it is painless and outpatient with immediate recovery, and has likely application for the treatment of other varicose veins and spider veins.
"We are very pleased to welcome Brent to the Company and feel extremely fortunate to have someone of his caliber join our firm. He has extensive global experience and a twenty-year track record of delivering superior business performance in highly competitive and difficult environments," commented Michael Cao, Chairman of the Board of Directors. "The Board believes that Brent's leadership will be the lynchpin to take the Ultroid® system to the next level through expanded sales and distribution, capturing the system's full potential in a multi-billion dollar segment."
Prior to joining Vascular Technologies, Inc. and Ultroid Technologies, Inc., Mr. Willis was the Chief Executive Officer for Cott Corporation (COT), the President of Asia Pacific and CCO for InBev (INB.BR), where he led the transformation of the Company into the world's largest brewer. Willis has also been a President in Latin America for the Coca-Cola Company (KO) and a Vice-President at Kraft Foods (KFT), where he started his business career following distinguished service in the United States Army. He holds a Masters of Business Administration from the University of Chicago and a Bachelor of Science in Engineering from the United States Military Academy at West Point.
"I am extremely excited to join Vascular Technologies and Ultroid®, and grow the Company from near inception to real significance while doing something good at the same time. Ultroid® is a far superior treatment and far more cost effective technology for a condition that affects most of the world's aging population. Expanding Ultroid® to meet that need is an opportunity too interesting to pass up," said Willis.
About Vascular Technologies and Ultroid Technologies
Vascular Technologies, Inc. is one of the fastest growing medical device companies in the United States. Its principal product is the breakthrough Ultroid® Medical System, a less expensive and more effective treatment than current procedures for the treatment of hemorrhoids with new applications for other varicose and spider veins. Ultroid® is a painless, non-invasive outpatient treatment with an over 90% effective rate that replaces ineffective over-the-counter creams and painful surgeries that can be accompanied by infection and prolonged recovery. The Ultroid® procedure can be performed by any physician, regardless of specialty, in their office, in approximately 10-15 minutes. Patients are able to resume their normal daily activities immediately, versus the several month recovery often associated with current laser and other surgical treatments. Ultroid® is FDA-cleared and accepted by most insurers and Medicare.
The Company's website is http://www.Ultroid.com. The brand names referenced in this press release are trademarks of Vascular Technologies, Inc. and Ultroid® Technologies, Inc. its affiliated companies, customers, or other third parties. The Company manages web video-enabled training clinics and markets and manufactures the Ultroid® Medical Devices.
Safe Harbor Statements
This press release may contain forward-looking statements reflecting management's current expectations regarding future results of operations, economic performance, financial condition and achievements of the Company. The forward-looking statements are based on the assumption that operating performance will continue to exponentially grow in line with recent trends and consistent with distribution expansion. Management believes these assumptions to be reasonable but there is no assurance that they will prove to be accurate. Forward-looking statements, specifically those concerning future performance are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.